CIAS
CRSP icon

Capital Investment Advisory Services’s CRISPR Therapeutics CRSP Stock Holding History

Capital Investment Advisory Services’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$260K Sell
4,761
-4,562
-49% -$240K 0.02% 634
2026
Q1 		$443K Sell
9,323
-2,625
-22% -$138K 0.03% 423
2025
Q4 		$627K Sell
11,948
-4,290
-26% -$257K 0.04% 336
2025
Q3 		$1.05M Sell
16,238
-3,533
-18% -$203K 0.08% 239
2025
Q2 		$962K Sell
19,771
-2,581
-12% -$99.9K 0.08% 232
2025
Q1 		$761K Buy
22,352
+87
+0.4% +$3.69K 0.07% 252
2024
Q4 		$876K Sell
22,265
-2,994
-12% -$141K 0.08% 206
2024
Q3 		$1.19M Sell
25,259
-4,727
-16% -$240K 0.11% 178
2024
Q2 		$1.62M Sell
29,986
-118
-0.4% -$6.83K 0.17% 129
2024
Q1 		$2.05M Sell
30,104
-1,532
-5% -$110K 0.22% 106
2023
Q4 		$1.98M Buy
31,636
+855
+3% +$47.3K 0.18% 101
2023
Q3 		$1.4M Buy
30,781
+925
+3% +$47.8K 0.14% 142
2023
Q2 		$1.68M Buy
29,856
+483
+2% +$27.4K 0.17% 107
2023
Q1 		$1.33M Buy
29,373
+2,108
+8% +$102K 0.16% 132
2022
Q4 		$1.11M Sell
27,265
-2,056
-7% -$109K 0.13% 148
2022
Q3 		$1.92M Buy
29,321
+1,092
+4% +$79.1K 0.25% 80
2022
Q2 		$1.72M Buy
28,229
+1,242
+5% +$73K 0.21% 96
2022
Q1 		$1.69M Buy
26,987
+6,591
+32% +$414K 0.18% 109
2021
Q4 		$1.55M Sell
20,396
-1,688
-8% -$147K 0.18% 124
2021
Q3 		$2.47M Sell
22,084
-529
-2% -$66.4K 0.31% 65
2021
Q2 		$3.66M Buy
22,613
+1,858
+9% +$226K 0.46% 49
2021
Q1 		$2.53M Buy
20,755
+4,025
+24% +$608K 0.36% 66
2020
Q4 		$2.56M Sell
16,730
-5,332
-24% -$630K 0.38% 59
2020
Q3 		$1.84M Sell
22,062
-4,775
-18% -$424K 0.35% 70
2020
Q2 		$1.97M Buy
26,837
+2,394
+10% +$140K 0.4% 62
2020
Q1 		$1.04M Buy
24,443
+935
+4% +$48.3K 0.25% 87
2019
Q4 		$1.43M Sell
23,508
-65
-0.3% -$3.55K 0.38% 54
2019
Q3 		$966K Sell
23,573
-695
-3% -$33.2K 0.27% 76
2019
Q2 		$1.2M Buy
24,268
+1,414
+6% +$56.5K 0.36% 51
2019
Q1 		$816K Sell
22,854
-2,425
-10% -$83.8K 0.3% 62
2018
Q4 		$722K Buy
25,279
+8,376
+50% +$291K 0.31% 63
2018
Q3 		$750K Sell
16,903
-1,060
-6% -$55.5K 0.35% 73
2018
Q2 		$1.06M Buy
17,963
+3,803
+27% +$217K 0.53% 43
2018
Q1 		$647K Buy
14,160
+3,860
+37% +$159K 0.36% 71
2017
Q4 		$242K Sell
10,300
-500
-5% -$9.5K 0.14% 153
2017
Q3 		$193K Buy
+10,800
New +$196K 0.12% 166

Other funds holding CRSP

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SC
Slow Capital Greenbrae, California $857M AUM 38.3% 1-Year Est. Return
CIC
Canal Insurance Company Greenville, South Carolina $456M AUM 40.11% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
WETS
Wealth Enhancement Trust Services Sioux Falls, South Dakota $900M AUM
BIP
Bouvel Investment Partners Phoenixville, Pennsylvania $442M AUM 70.77% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
LIM
Leavell Investment Management Mobile, Alabama $2.74B AUM 26.51% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Capital Investment Advisory Services's CRSP Position: Q2 2026 in Review

Capital Investment Advisory Services reduced its CRISPR Therapeutics (CRSP) stake by 49% in Q2 2026, selling an estimated $240K and leaving 4,761 shares worth $260K. The position accounts for 0.02% of the portfolio, ranked #634.

Capital Investment Advisory Services first reported a position in CRSP in Q3 2017 and has held it in 36 quarters since. The position peaked at $3.66M in Q2 2021. 97 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Capital Investment Advisory Services held 4,761 shares of CRISPR Therapeutics worth $260K as of Q2 2026.
  • Capital Investment Advisory Services sold 4,562 CRISPR Therapeutics shares in Q2 2026, an estimated $240K.
  • CRISPR Therapeutics made up 0.02% of Capital Investment Advisory Services's portfolio in Q2 2026, its #634 holding.
  • Capital Investment Advisory Services first reported a position in CRISPR Therapeutics in Q3 2017 and has held it in 36 quarters since.
  • Capital Investment Advisory Services's CRISPR Therapeutics position peaked at $3.66M in Q2 2021.
  • 97 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Capital Investment Advisory Services's 13F filing for Q2 2026, filed 23 Jul 2026.